DualityBio-B (09606) Directors and Senior Management Make Voluntary Lock-Up Commitment, Expressing Confidence in the Company's Growth Prospects

Stock News10-29

DualityBio-B (09606) announced that the company's directors and senior management have full confidence in the company's long-term value and future development prospects.

The board of directors has been informed that, based on this confidence, Dr. Zhu Zhongyuan, Chairman of the Board, Executive Director and Chief Executive Officer; Mr. Zhang Shaoren, Executive Director and Chief Financial Officer; Dr. Hua Haiqing, Executive Director, Senior Vice President and Head of Drug Discovery; Dr. Qiu Yang, Chief Scientific Officer and General Manager of Dualitybio Inc.; Dr. Mou Hua, Global Chief Medical Officer; Ms. Si Wen, Executive Director of Human Resources; Mr. Yu Xin, Vice President and Head of Regulatory Affairs; Ms. Zhou Lan, Vice President of Business Strategy; and Ms. Yuan Jiali, Vice President, Head of Legal and Compliance and Joint Company Secretary, have voluntarily undertaken not to initiate or instruct others to conduct any transactions involving the sale or other disposal of shares of the company directly or indirectly beneficially owned by them, including any shares obtained through the exercise of share options during the lock-up period, for a period of six months, commencing from October 29, 2026 (i.e., from October 29, 2026 to April 28, 2027, inclusive of both dates).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1159932734?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-29 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159932734","market":"sg","top_or_hot":-1,"title":"DualityBio-B (09606) Directors and Senior Management Make Voluntary Lock-Up Commitment, Expressing Confidence in the Company's Growth Prospects","media":"Stock News","content":"<p>DualityBio-B (09606) announced that the company's directors and senior management have full confidence in the company's long-term value and future development prospects.<br><br>The board of directors has been informed that, based on this confidence, Dr. Zhu Zhongyuan, Chairman of the Board, Executive Director and Chief Executive Officer; Mr. Zhang Shaoren, Executive Director and Chief Financial Officer; Dr. Hua Haiqing, Executive Director, Senior Vice President and Head of Drug Discovery; Dr. Qiu Yang, Chief Scientific Officer and General Manager of Dualitybio Inc.; Dr. Mou Hua, Global Chief Medical Officer; Ms. Si Wen, Executive Director of Human Resources; Mr. Yu Xin, Vice President and Head of Regulatory Affairs; Ms. Zhou Lan, Vice President of Business Strategy; and Ms. Yuan Jiali, Vice President, Head of Legal and Compliance and Joint Company Secretary, have voluntarily undertaken not to initiate or instruct others to conduct any transactions involving the sale or other disposal of shares of the company directly or indirectly beneficially owned by them, including any shares obtained through the exercise of share options during the lock-up period, for a period of six months, commencing from October 29, 2026 (i.e., from October 29, 2026 to April 28, 2027, inclusive of both dates).<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DualityBio-B (09606) Directors and Senior Management Make Voluntary Lock-Up Commitment, Expressing Confidence in the Company's Growth Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDualityBio-B (09606) Directors and Senior Management Make Voluntary Lock-Up Commitment, Expressing Confidence in the Company's Growth Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-29 18:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DualityBio-B (09606) announced that the company's directors and senior management have full confidence in the company's long-term value and future development prospects.<br><br>The board of directors has been informed that, based on this confidence, Dr. Zhu Zhongyuan, Chairman of the Board, Executive Director and Chief Executive Officer; Mr. Zhang Shaoren, Executive Director and Chief Financial Officer; Dr. Hua Haiqing, Executive Director, Senior Vice President and Head of Drug Discovery; Dr. Qiu Yang, Chief Scientific Officer and General Manager of Dualitybio Inc.; Dr. Mou Hua, Global Chief Medical Officer; Ms. Si Wen, Executive Director of Human Resources; Mr. Yu Xin, Vice President and Head of Regulatory Affairs; Ms. Zhou Lan, Vice President of Business Strategy; and Ms. Yuan Jiali, Vice President, Head of Legal and Compliance and Joint Company Secretary, have voluntarily undertaken not to initiate or instruct others to conduct any transactions involving the sale or other disposal of shares of the company directly or indirectly beneficially owned by them, including any shares obtained through the exercise of share options during the lock-up period, for a period of six months, commencing from October 29, 2026 (i.e., from October 29, 2026 to April 28, 2027, inclusive of both dates).<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252160.HKD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","start_time":0,"source_url":"","article_id":"1159932734","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159932734","pubTimestamp":1793268375,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"DualityBio-B (09606) announced that the company's directors and senior management have full confidence in the company's long-term value and future development prospects.The board of directors has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","09606":"映恩生物-B","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","BK1161":"生物科技","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元"},"translate_title":"DualityBio-B(09606)董事及高级管理人员作出自愿锁定承诺，对公司增长前景充满信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"DualityBio-B (09606) announced that the company's directors and senior management have full confidence in the company's long-term value and future development prospects.The board of directors has been informed that, based on this confidence, Dr. Zhu Zhongyuan, Chairman of the Board, Executive Director and Chief Executive Officer; Mr. Zhang Shaoren, Executive Director and Chief Financial Officer; Dr. Hua Haiqing, Executive Director, Senior Vice President and Head of Drug Discovery; Dr. Qiu Yang, Chief Scientific Officer and General Manager of Dualitybio Inc.; Dr. Mou Hua, Global Chief Medical Officer; Ms. Si Wen, Executive Director of Human Resources; Mr. Yu Xin, Vice President and Head of Regulatory Affairs; Ms. Zhou Lan, Vice President of Business Strategy; and Ms. Yuan Jiali, Vice President, Head of Legal and Compliance and Joint Company Secretary, have voluntarily undertaken not to initiate or instruct others to conduct any transactions involving the sale or other disposal of shares of the company directly or indirectly beneficially owned by them, including any shares obtained through the exercise of share options during the lock-up period, for a period of six months, commencing from October 29, 2026 (i.e., from October 29, 2026 to April 28, 2027, inclusive of both dates).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159932734","isCrawlerRequest":true}